Compare Stocks → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXNNASDAQ:ALRNNASDAQ:APTXNASDAQ:FWPNASDAQ:IMNM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$15.41-0.9%$14.43$5.00▼$27.90$16.48M1.6616,716 shs5,074 shsALRNAileron Therapeutics$5.06+2.6%$5.41$1.01▼$7.42$85.87M2.2264,769 shs80,550 shsAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/AIMNMImmunome$14.26-0.1%$22.25$4.44▼$30.96$851.18M1.66725,369 shs736,699 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-0.90%-26.48%+24.88%+26.10%+2.76%ALRNAileron Therapeutics+2.64%+1.20%-12.46%+0.40%+255.09%APTXAptinyx0.00%0.00%0.00%0.00%-22.33%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%IMNMImmunome-0.07%-17.00%-43.84%-18.42%+169.06%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics0.3311 of 5 stars0.03.00.00.02.40.80.6ALRNAileron Therapeutics1.3237 of 5 stars3.53.00.00.00.61.70.0APTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AIMNMImmunome1.538 of 5 stars3.50.00.00.02.61.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics2.00HoldN/AN/AALRNAileron Therapeutics3.00Buy$19.00275.49% UpsideAPTXAptinyxN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AIMNMImmunome3.00Buy$32.67129.08% UpsideCurrent Analyst RatingsLatest ALRN, IMNM, APTX, ADXN, and FWP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/15/2024IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/1/2024IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $33.001/29/2024IMNMImmunomeLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/29/2024IMNMImmunomeSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$1.61M10.13N/AN/A$1.20 per share12.84ALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/AFWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/AIMNMImmunome$14.02M60.71N/AN/A$2.77 per share5.15Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$19.27N/AN/AN/A-653.33%-277.44%-156.74%5/9/2024 (Estimated)ALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)APTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/AFWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AIMNMImmunome-$106.81M-$5.39N/AN/AN/A-761.92%-69.74%-31.40%5/3/2024 (Estimated)Latest ALRN, IMNM, APTX, ADXN, and FWP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q4 2023ALRNAileron TherapeuticsN/A-$1.54-$1.54-$1.54N/AN/A3/28/2024Q4 2023IMNMImmunome-$0.28-$0.54-$0.26$3.14$3.40 million$3.83 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AALRNAileron TherapeuticsN/AN/AN/AN/AN/AAPTXAptinyxN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A1.461.46ALRNAileron TherapeuticsN/A4.174.17APTXAptinyxN/AN/AN/AFWPForward Pharma A/SN/A18.43N/AIMNMImmunomeN/A6.636.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%ALRNAileron Therapeutics90.89%APTXAptinyxN/AFWPForward Pharma A/S12.57%IMNMImmunome44.58%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%ALRNAileron Therapeutics5.57%APTXAptinyx10.97%FWPForward Pharma A/S71.47%IMNMImmunome20.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics241.06 million901,000Not OptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableAPTXAptinyx12N/AN/ANot OptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableIMNMImmunome5559.69 million47.76 millionOptionableALRN, IMNM, APTX, ADXN, and FWP HeadlinesSourceHeadlineImmunome Appoints Sandra M. Swain to Board of Directorsbusinesswire.com - April 25 at 8:26 AM61,346 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by Cerity Partners LLCmarketbeat.com - April 24 at 4:43 AMImmunome (NASDAQ:IMNM) Shares Gap Up to $15.48marketbeat.com - April 22 at 12:49 PMImmunome (NASDAQ:IMNM) Shares Down 3.3% americanbankingnews.com - April 21 at 4:56 AMImmunome, Inc. (IMNM)finance.yahoo.com - April 19 at 1:00 AMImmunome, Inc. (NASDAQ:IMNM) Receives $31.50 Consensus Target Price from Brokeragesamericanbankingnews.com - April 18 at 1:14 AMImmunome (IMNM) Price Target Increased by 8.72% to 36.04msn.com - April 17 at 1:59 PMImmunome (NASDAQ:IMNM) Shares Gap Up to $20.58americanbankingnews.com - April 17 at 5:16 AMGuggenheim Initiates Coverage of Immunome (IMNM) with Buy Recommendationmsn.com - April 16 at 1:11 PMImmunome (NASDAQ:IMNM) Receives New Coverage from Analysts at Guggenheimamericanbankingnews.com - April 16 at 4:46 AMEmfo LLC Buys Shares of 59,165 Immunome, Inc. (NASDAQ:IMNM)marketbeat.com - April 15 at 6:38 PMImmunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - April 15 at 8:23 AMImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meetingbusinesswire.com - April 5 at 8:00 AMImmunome (NASDAQ:IMNM) Trading Down 4.5%marketbeat.com - April 4 at 6:20 PMQ1 2024 EPS Estimates for Immunome, Inc. (NASDAQ:IMNM) Reduced by Wedbushmarketbeat.com - April 4 at 8:32 AMNew Strong Sell Stocks for April 4thzacks.com - April 4 at 7:01 AMWedbush Weighs in on Immunome, Inc.'s Q1 2025 Earnings (NASDAQ:IMNM)marketbeat.com - April 3 at 6:30 AMImmunome (NASDAQ:IMNM) Given New $33.00 Price Target at Wedbushmarketbeat.com - April 1 at 8:30 AMLeerink Partnrs Weighs in on Immunome, Inc.'s Q1 2024 Earnings (NASDAQ:IMNM)marketbeat.com - March 29 at 8:16 AMIMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 29 at 2:01 AMTD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)markets.businessinsider.com - March 28 at 11:33 PMImmunome (NASDAQ:IMNM) Shares Down 3.7% marketbeat.com - March 28 at 4:33 PMImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assetsbusinesswire.com - March 28 at 4:06 PMImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assetsbusinesswire.com - March 28 at 4:02 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsNASDAQ:ADXNAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Aileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.AptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Forward Pharma A/SNASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.ImmunomeNASDAQ:IMNMImmunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.